Psoriasis Clinical Trial

A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis

Summary

This is a study to assess the long-term safety and tolerability of bimekizumab in subjects with psoriatic arthritis

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

In the opinion of the Investigator, the subject is expected to benefit from participation in an Open Label Extension (OLE) study
Subject completed PA0008 without meeting any withdrawal criteria
Female subjects must be postmenopausal, permanently sterilized or, if of childbearing potential, must be willing to use a highly effective method of contraception
Male subjects with a partner of childbearing potential must be willing to use a condom when sexually active

Exclusion Criteria:

Female subjects who plan to become pregnant during the study or within 20 weeks following the last dose of IMP. Male subjects who are planning a partner pregnancy during the study or within 20 weeks following the last dose
Subjects with any current sign or symptom that may indicate a medically significant active infection (except for the common cold) or has had an infection requiring systemic antibiotics within 2 weeks of study entry
Subjects who meet any withdrawal criteria in PA0008. For any subject with an ongoing Serious Adverse Event, or a history of serious infections (including hospitalizations) in the lead-in study, the Medical Monitor must be consulted prior to the subject's entry into PA0009

Study is for people with:

Psoriasis

Phase:

Phase 2

Estimated Enrollment:

184

Study ID:

NCT03347110

Recruitment Status:

Completed

Sponsor:

UCB Biopharma SRL

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 11 Locations for this study

See Locations Near You

Pa0009 025
Lexington Kentucky, 40504, United States
Pa0009 003
Hagerstown Maryland, 21502, United States
Pa0009 011
Lansing Michigan, 48910, United States
Pa0009 028
Rochester New York, 14642, United States
Pa0009 014
Portland Oregon, 97239, United States
Pa0009 001
Duncansville Pennsylvania, 16635, United States
Pa0009 012
Johnston Rhode Island, 02919, United States
Pa0009 004
Charleston South Carolina, 29406, United States
Pa0009 010
Jackson Tennessee, 38305, United States
Pa0009 006
Dallas Texas, 75231, United States
Pa0009 013
Mesquite Texas, 75150, United States
Pa0009 205
Brno , , Czechia
Pa0009 207
Olomouc , , Czechia
Pa0009 210
Praha 11 , , Czechia
Pa0009 201
Praha 4 , , Czechia
Pa0009 202
Praha , , Czechia
Pa0009 203
Zlín , , Czechia
Pa0009 302
Cologne , , Germany
Pa0009 309
Erlangen , , Germany
Pa0009 304
Hamburg , , Germany
Pa0009 301
Ratingen , , Germany
Pa0009 403
Budapest , , Hungary
Pa0009 401
Veszprém , , Hungary
Pa0009 452
Bialystok , , Poland
Pa0009 453
Elbląg , , Poland
Pa0009 456
Elbląg , , Poland
Pa0009 455
Kraków , , Poland
Pa0009 451
Poznań , , Poland
Pa0009 450
Toruń , , Poland
Pa0009 454
Warsaw , , Poland
Pa0009 459
Warsaw , , Poland
Pa0009 465
Wrocław , , Poland
Pa0009 604
Moscow , , Russian Federation
Pa0009 605
Moscow , , Russian Federation
Pa0009 607
Moscow , , Russian Federation
Pa0009 606
Saint Petersburg , , Russian Federation
Pa0009 608
Saint Petersburg , , Russian Federation

How clear is this clinincal trial information?

Study is for people with:

Psoriasis

Phase:

Phase 2

Estimated Enrollment:

184

Study ID:

NCT03347110

Recruitment Status:

Completed

Sponsor:


UCB Biopharma SRL

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.